- Potential safety hazards during the production or quality inspection of drugs
- Potential safety hazards discovered in the complaint management procedures
- Notices on defects from material suppliers
- Regulatory authorities’ requirements on drug recalls and inquiries of drug quality by other authoritative institutions
Ascentage Pharma Group International (Incorporated in the Cayman Islands with limited liability)
Greenhouse gas emissions & sustainability report data
In its 2019 reporting, Ascentage Pharma Group International (Incorporated in the Cayman Islands with limited liability) disclosed greenhouse gas emissions of 907.28 ton of CO2 equivalent. By scope: Scope 2: 900.91 ton of CO2 equivalent. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
907.28 ton of CO2 equivalent
2019
Water Usage
4.4K m3
2019
Waste
4.4K tons
2019
Energy Use
1.3M kWh
2019
📊 Emissions by Scope (2019)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 900.91 ton of CO2 equivalent |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- Reduced emissions of pollutants to atmosphere, soil and waters by constantly improving process and implementing management and operation responsibility system
- Implemented waste management system to regulate the management of waste collection, classification, storage, transfer and disposal
🌱 ESG Focus Areas
Environmental responsibilityLabor responsibilityOperational responsibilityCorporate governance responsibility